Ultrasensitive ctDNA testing distinguishes patients with very different risks for recurrence — but it remains to be seen whether acting on the results can improve their outcomes.

Ten-year findings suggest some patients may safely receive less treatment, potentially lowering side effects without raising ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant chemotherapy significantly lowered 90-day postoperative mortality for advanced ovarian cancer across ...

REGIONAL nodal irradiation in breast cancer showed low recurrence rates after nodal pCR, even when residual breast disease ...

The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to ...

Please provide your email address to receive an email when new articles are posted on . Patients with pathologic complete response after neoadjuvant systemic therapy remained disease-free at 5 years ...

A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.

Neoadjuvant chemotherapy did not improve disease-free survival compared with upfront surgery in patients with locally advanced colon cancer in a randomized trial. However, neoadjuvant chemotherapy did ...

Neoadjuvant immunotherapy plus chemotherapy shows a 35% pathological complete response rate and 49% major pathological response rate in LS-SCLC. Most patients achieved R0 surgical resection, with a 44 ...

Long-term data from a prospective phase 2 trial show neoadjuvant cisplatin-based chemotherapy before nephroureterectomy provides durable survival benefits in high-risk, nonmetastatic UTUC. Neoadjuvant ...